Aligos Therapeutics, a clinical-stage biotech company focused on liver and viral diseases, announced it will release its second quarter 2026 financial results on August 6, 2026, before U.S. markets open. The company is known for developing therapies targeting chronic hepatitis B virus infection. This upcoming report will provide investors with insights into the company's financial health and progress in its drug development pipeline.
Bastion Intelligence has enhanced BastionGPT with advanced document processing and OCR, enabling healthcare professionals to upload and analyze over 1,000 pages of clinical and administrative records in a HIPAA-compliant environment. The platform sup...
TG Therapeutics reported mixed Q2 2026 results with total revenue of $240.34 million, beating estimates thanks to strong sales of its drug BRIUMVI, which grew over 64% year-over-year. However, earnings per share (EPS) came in at $0.05, significantly ...
ON Semiconductor is set to report its Q3 earnings with analysts expecting an EPS of $0.72 and revenue around $1.59 billion, marking an 8% increase year-over-year. The company's growth is mainly supported by strong demand in automotive and industrial ...
Amundi conducted a share buyback program from July 27 to July 31, 2026, repurchasing a total of 200,000 shares. The average purchase price during this period was €90.90 per share. This move is part of Amundi's ongoing strategy to manage its capital s...
Amazon-owned Zoox has received federal approval to deploy the first steering-wheel-free robotaxis commercially in the U.S., pending state and local permissions. This milestone in autonomous vehicle technology introduces new legal challenges, especial...
